Comparison of six different commercial IgG-ELISA kits for the detection of TBEV-antibodies

被引:47
作者
Niedrig, M
Vaisviliene, D
Teichmann, A
Klockmann, U
Biel, SS
机构
[1] Robert Koch Inst, D-13353 Berlin, Germany
[2] Ctr Communicable Dis Prevent & Control, LT-2042 Vilnius, Lithuania
[3] Chiron Behring GMBH, D-35041 Marburg, Germany
关键词
cross-reactivity; enzyme immune-assay; tick-borne encephalitis virus;
D O I
10.1016/S1386-6532(00)00178-5
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Tick-borne encephalitis virus (TBEV) is a pathogenic human flavivirus endemic in some parts of Europe and Asia. Commercial enzyme immunoassays (EIA) for the detection of IgG antibodies are often used in TBEV-seroprevalence studies, as well as for the confirmation of a successful vaccination against TBEV. However, the detection of TBEV-specific antibodies can be biased by the cross-reactivity between different flavivirus genera. Objectives: To compare different EIA test systems for the detection of TBEV-IgG antibodies. Study design: Six commercial EIA kits for the detection of TBEV-specific antibodies are compared, using serum panels (n = 139) of subjects with a documented clinical history (109 sera from TBEV infected patients, 30 sera from people vaccinated against TBEV). For the analysis of possible cross-reactivities, 24 sera from yellow fever vaccinated people and 13 sera positive for Dengue virus-specific antibodies were also included. Results: The sensitivity of the different TBEV test systems ranges from 73 to 99%. However, when testing the yellow fever and Dengue virus positive specimens, problems with the flavivirus cross- reactivity become obvious, resulting in specificities between 14 and 81%. Conclusions: This study shows the necessity of further improvement of the existing TBEV test systems regarding both sensitivity and specificity. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:179 / 182
页数:4
相关论文
共 9 条
[1]   Diagnosis of tick-borne encephalitis: Evaluation of sera with borderline titers with the TBE-ELISA [J].
Dobler, G ;
Treib, J ;
Kiessig, ST ;
vonBlohn, W ;
Frosner, G ;
Haass, A .
INFECTION, 1996, 24 (05) :405-406
[2]  
Gassmann C, 1997, J MED VIROL, V51, P242, DOI 10.1002/(SICI)1096-9071(199703)51:3&lt
[3]  
242::AID-JMV17&gt
[4]  
3.0.CO
[5]  
2-M
[6]   THE MOLECULAR-BIOLOGY OF TICK-BORNE ENCEPHALITIS-VIRUS [J].
HEINZ, FX ;
MANDL, CW .
APMIS, 1993, 101 (10) :735-745
[7]   HUMORAL IMMUNITY AGAINST TICK-BORNE ENCEPHALITIS-VIRUS FOLLOWING MANIFEST DISEASE AND ACTIVE IMMUNIZATION [J].
KLOCKMANN, U ;
BOCK, HL ;
KWASNY, H ;
PRAUS, M ;
CIHLOVA, V ;
TOMKOVA, E ;
KRIVANEC, K .
VACCINE, 1991, 9 (01) :42-46
[8]   Vaccination against tick-borne encephalitis virus, a flavivirus, prevents disease but not infection, although viremia is undetectable [J].
Kreil, TR ;
Maier, E ;
Fraiss, S ;
Attakpah, E ;
Burger, I ;
Mannhalter, JW ;
Eibl, MM .
VACCINE, 1998, 16 (11-12) :1083-1086
[9]  
ROGGENDORF M, 1981, J MED VIROL, V7, P1950